-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023:

- 287,160 shares
- € 156,554.06
- Number of executions on buy side on semester: 509
- Number of executions on sell side on semester: 492
- Traded volume on buy side on semester: 634,648 shares for € 258,705.74
- Traded volume on sell side on semester: 923,185 shares for € 402,719.91

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:

- 574,697 shares
- € 10,983.50
- Number of executions on buy side on semester: 349
- Number of executions on sell side on semester: 236
- Traded volume on buy side on semester: 335,452 shares for € 82,028.30
- Traded volume on sell side on semester: 208,189 shares for € 59,090.63

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

  Achats   Ventes
  Nombre de
transactions		 Nombre de
titres		 Capitaux en EUR   Nombre de
transactions		 Nombre de
titres		 Capitaux en EUR
Total

509

634 648

258 705.74

 

492

923 185

402 719.91

02/01/2023

5

3 151

441.14

 

2

3 999

559.86

03/01/2023

1

1

0.14

 

2

2 001

300.15

04/01/2023

-

-

-

 

24

40 556

7 705.64

05/01/2023

-

-

-

 

12

19 485

3 897.00

06/01/2023

-

-

-

 

55

105 795

30 680.55

09/01/2023

-

-

-

 

28

42 000

16 800.00

10/01/2023

-

-

-

 

40

105 000

57 750.00

11/01/2023

87

128 000

66 560.00

 

56

145 000

92 800.00

12/01/2023

33

60 000

25 200.00

 

-

-

-

13/01/2023

17

20 000

8 800.00

 

21

55 000

24 750.00

16/01/2023

29

36 000

17 280.00

 

34

70 000

35 000.00

17/01/2023

16

24 000

10 800.00

 

5

15 000

7 050.00

18/01/2023

11

8 000

3 680.00

 

1

5 000

2 350.00

19/01/2023

13

20 000

8 600.00

 

1

5 000

2 150.00

20/01/2023

10

16 000

6 400.00

 

4

10 000

4 100.00

23/01/2023

2

2 000

800.00

 

4

10 000

4 300.00

24/01/2023

14

15 951

7 018.44

 

12

25 000

11 250.00

25/01/2023

2

4 000

1 760.00

 

6

5 000

2 250.00

26/01/2023

4

8 000

3 840.00

 

25

57 000

27 930.00

27/01/2023

5

10 000

4 700.00

 

1

5 000

2 500.00

30/01/2023

5

10 000

4 500.00

 

2

5 000

2 250.00

31/01/2023

1

2 000

880.00

 

-

-

-

01/02/2023

4

2 049

881.07

 

1

5 000

2 200.00

02/02/2023

1

2 000

860.00

 

-

-

-

03/02/2023

12

18 000

7 380.00

 

3

5 000

2 050.00

06/02/2023

2

1 795

753.90

 

3

15 000

6 300.00

07/02/2023

1

205

86.10

 

1

5 000

2 150.00

08/02/2023

3

3 783

1 588.86

 

-

-

-

09/02/2023

2

2 217

908.97

 

-

-

-

10/02/2023

21

6 000

2 400.00

 

1

5 000

2 100.00

13/02/2023

2

4 000

1 600.00

 

1

5 000

2 100.00

14/02/2023

3

2 001

780.39

 

2

5 001

2 050.41

15/02/2023

1

1

0.40

 

1

1

0.40

16/02/2023

5

4 000

1 560.00

 

-

-

-

17/02/2023

4

7 000

2 730.00

 

-

-

-

20/02/2023

3

4 000

1 560.00

 

1

5 000

2 050.00

21/02/2023

1

2 000

760.00

 

-

-

-

22/02/2023

1

2 000

760.00

 

-

-

-

23/02/2023

12

16 000

5 760.00

 

-

-

-

24/02/2023

3

3 300

1 122.00

 

-

-

-

27/02/2023

4

2 000

700.00

 

3

2 000

720.00

28/02/2023

5

10 000

3 500.00

 

-

-

-

09/03/2023

1

147

49.98

 

-

-

-

10/03/2023

4

3 386

1 151.24

 

-

-

-

13/03/2023

7

10 655

3 516.15

 

-

-

-

14/03/2023

-

-

-

 

1

1

0.33

15/03/2023

1

2 000

620.00

 

-

-

-

16/03/2023

2

2 000

600.00

 

-

-

-

17/03/2023

1

2 000

600.00

 

-

-

-

20/03/2023

7

6 000

1 740.00

 

-

-

-

22/03/2023

5

10 000

2 600.00

 

1

2 000

560.00

23/03/2023

-

-

-

 

2

491

142.39

27/03/2023

5

4 000

1 120.00

 

-

-

-

28/03/2023

2

4 000

1 080.00

 

-

-

-

29/03/2023

-

-

-

 

3

2 000

560.00

30/03/2023

-

-

-

 

12

13 509

4 052.70

31/03/2023

-

-

-

 

17

21 999

7 259.67

03/04/2023

1

2 000

660.00

 

11

17 000

6 120.00

04/04/2023

1

2 000

660.00

 

4

6 000

2 220.00

05/04/2023

-

-

-

 

8

8 000

2 880.00

06/04/2023

-

-

-

 

4

4 000

1 520.00

11/04/2023

4

4 159

1 538.83

 

4

4 000

1 560.00

12/04/2023

4

3 841

1 421.17

 

3

2 001

780.39

13/04/2023

4

2 000

740.00

 

-

-

-

14/04/2023

5

8 000

2 800.00

 

3

2 000

740.00

17/04/2023

5

8 000

2 720.00

 

-

-

-

18/04/2023

5

8 000

2 560.00

 

3

2 340

748.80

20/04/2023

5

6 000

1 800.00

 

-

-

-

21/04/2023

1

2 000

600.00

 

-

-

-

24/04/2023

5

6 000

1 740.00

 

-

-

-

25/04/2023

5

10 000

2 800.00

 

3

6 000

1 740.00

26/04/2023

9

8 000

2 320.00

 

-

-

-

27/04/2023

-

-

-

 

6

2 000

580.00

28/04/2023

1

2 000

560.00

 

4

6 000

1 800.00

03/05/2023

4

1 000

290.00

 

-

-

-

04/05/2023

6

2 000

580.00

 

2

1 000

300.00

05/05/2023

-

-

-

 

3

243

72.90

08/05/2023

-

-

-

 

6

7 757

2 327.10

09/05/2023

1

2 000

580.00

 

-

-

-

10/05/2023

3

6 000

1 680.00

 

-

-

-

11/05/2023

1

1

0.29

 

3

1 911

554.19

15/05/2023

-

-

-

 

1

90

26.10

16/05/2023

4

2 000

560.00

 

-

-

-

17/05/2023

3

4 000

1 080.00

 

-

-

-

18/05/2023

-

-

-

 

2

2 000

560.00

19/05/2023

2

4 000

1 080.00

 

7

5 000

1 400.00

22/05/2023

1

2 000

540.00

 

-

-

-

23/05/2023

-

-

-

 

4

3 000

840.00

24/05/2023

2

4 000

1 080.00

 

-

-

-

25/05/2023

1

1

0.27

 

1

1

0.27

26/05/2023

1

1

0.27

 

3

1 315

368.20

29/05/2023

-

-

-

 

2

686

192.08

31/05/2023

2

88

23.76

 

-

-

-

01/06/2023

2

1 912

516.24

 

-

-

-

05/06/2023

-

-

-

 

3

2 000

560.00

06/06/2023

2

2 000

540.00

 

-

-

-

12/06/2023

4

6 000

1 560.00

 

-

-

-

13/06/2023

2

2 000

500.00

 

-

-

-

14/06/2023

4

2 001

500.25

 

3

4 001

1 040.26

15/06/2023

4

2 000

520.00

 

-

-

-

16/06/2023

-

-

-

 

3

2 000

520.00

19/06/2023

4

2 537

659.62

 

-

-

-

20/06/2023

2

1 464

366.00

 

1

1

0.26

21/06/2023

4

2 000

520.00

 

-

-

-

22/06/2023

-

-

-

 

1

2 000

520.00

23/06/2023

3

2 000

520.00

 

1

2 000

520.00

26/06/2023

1

2 000

500.00

 

2

2 000

520.00

27/06/2023

5

2 400

624.00

 

1

2 000

520.00

28/06/2023

-

-

-

 

1

2 000

520.00

29/06/2023

6

3 601

936.26

 

1

1

0.26

 

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
+33 1 45 58 76 00

Media Relations
Arthur Rouillé
NewCap
valeriotx@newcap.eu
+33 1 44 71 00 15

Investor Relations / Strategic Communication
Dušan Orešanský / Nicolas Fossiez
NewCap
valeriotx@newcap.eu
+33 1 44 71 94 92

Valerio Therapeutics

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
+33 1 45 58 76 00

Media Relations
Arthur Rouillé
NewCap
valeriotx@newcap.eu
+33 1 44 71 00 15

Investor Relations / Strategic Communication
Dušan Orešanský / Nicolas Fossiez
NewCap
valeriotx@newcap.eu
+33 1 44 71 94 92

More News From Valerio Therapeutics

Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter “Valerio Therapeutics” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2023, and provides an update on its activities. Dr. Shefali Agarwal, President and CEO of Valerio Therapeutics, said: “The first half of 2023 wa...

Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Meeting of June 6, 2023

PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights. The Annual General Meeting followed the voting rec...

Onxeo: Combined General Meeting of June 6, 2023: Availability of Preparatory Documents and Participation & Voting Procedures

PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the availability of preparatory documents for its Combined General Meeting to be held on Tuesday, June 6, 2023 at 2:00 pm at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris. The notice of meeting, includin...
Back to Newsroom